Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Grants Priority Review to Osimertinib Plus Chemotherapy for EGFR+ Locally Advanced or Metastatic NSCLC

October 16th 2023

The FDA has granted priority review to the supplemental new drug application seeking the approval of osimertinib in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non–small cell lung cancer.

European Commission Approves Adjuvant Pembrolizumab for High-Risk NSCLC

October 16th 2023

The European Commission has approved pembrolizumab as adjuvant monotherapy for the treatment of adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Ceralasertib/Durvalumab Demonstrates Efficacy in RAS-Mutant Advanced NSCLC Post Immune Checkpoint Blockade

October 14th 2023

Treatment with the combination of ceralasertib and durvalumab elicited preliminary efficacy signals in patients with advanced non–small cell lung cancer with and without RAS mutations who received prior treatment with immune checkpoint blockade.

Best Practices for Patient Education Surrounding Cancer Treatment

October 13th 2023

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

Molecular Testing Considerations in Cancer Treatment

October 13th 2023

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

Dr Gondi on Prophylactic Cranial Irradiation With Hippocampal Avoidance in SCLC

October 13th 2023

Vinai Gondi, MD, discusses efficacy and safety findings from the phase 2/3 NRG-CC003 trial of prophylactic cranial irradiation in patients with small cell lung cancer.

NVL-655 Elicits Preliminary Activity, Safety in Heavily Pretreated, ALK+ Advanced NSCLC

October 13th 2023

Treatment with the novel, ALK-selective TKI NVL-655 generated responses and was well tolerated in heavily pretreated patients with ALK-positive, advanced non–small cell lung cancer.

FDA Approves Companion Diagnostics for Encorafenib/Binimetinib in BRAF V600E+ Metastatic NSCLC

October 13th 2023

The FDA has approved FoundationOne® CDx and FoundationOne Liquid CDx for use as companion diagnostics to identify patients with metastatic non–small cell lung cancer harboring BRAF V600E mutations who may benefit from treatment with the combination of encorafenib plus binimetinib.

Dr Salgia on Unmet Needs Associated With Treatment-Related Toxicity in Lung Cancer

October 12th 2023

Ravi Salgia, MD, PhD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting unmet needs that remain regarding treatment-related toxicities that can arise with commonly used agents in patients with lung cancer.

Dr Massarelli on the Current SCLC Treatment Armamentarium

October 12th 2023

Erminia Massarelli, MD, PhD, MS, discusses clinical gaps in lung cancer care that were highlighted at the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of molecular testing in patients with small cell lung cancer and collaborations between health care networks in this treatment arena.

Dr Patel on Establishing a Consensus for Lung Cancer Treatment

October 12th 2023

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting the similarities and differences between treating lung cancer in community oncology settings vs academic medical center settings.

Treatment Options for EGFR-Mutated NSCLC Following Progression

October 12th 2023

Sandip P. Patel, MD, discusses treatment options available for patients with EGFR-mutated NSCLC who progress on EGFR TKIs and platinum-based chemotherapy.

Current Treatment Landscape for EGFR-Mutated NSCLC

October 12th 2023

Medical oncologists specializing in lung cancer give an overview of the current treatment landscape for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Dr Iams on the Effect of the FLAURA2 Trial in EGFR-Mutant NSCLC

October 12th 2023

Wade T. Iams, MD, discusses the impact of the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer, highlighting the notable improvements in progression-free survival that the approach elicits.

Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape

October 10th 2023

Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.

Emerging Targets in Non–Small Cell Lung Cancer

October 10th 2023

Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.

Perioperative Pembrolizumab Meets Dual Primary End Point of OS in NSCLC

October 10th 2023

Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.

Dr Harpole on the Design of an Exploratory Analysis of the AEGEAN Trial in NSCLC

October 7th 2023

David Harpole, MD, discusses on the rationale and design of an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer, which he presented at the 2023 IASLC World Conference on Lung Cancer.

Biomarker Testing in Gastrointestinal and Lung Cancers

October 6th 2023

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

Molecular Testing in Breast Cancer

October 6th 2023

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.